Fabry Disesase

Rare Diseases
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GC Biopharma
GC BiopharmaKorea - Yongin
1 program
1
HM15421/GC1134APhase 1/21 trial
Active Trials
NCT06858397RecruitingEst. Aug 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
GC BiopharmaHM15421/GC1134A

Clinical Trials (1)

A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease

Start: May 2025Est. completion: Aug 2028
Phase 1/2Recruiting

Related Jobs in Rare Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
1 companies competing in this space